UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 86

Sortiert nach

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

The American journal of psychiatry, 2008-08, Vol.165 (8), p.1033-1039

2008

Volltextzugriff (PDF)

The Discovery of Fluoxetine Hydrochloride (Prozac)

Nature reviews. Drug discovery, 2005-09, Vol.4 (9), p.764-774

2005

Volltextzugriff (PDF)

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

Pharmacological reviews, 2008-09, Vol.60 (3), p.358

2008

Volltextzugriff (PDF)

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Neuropharmacology, 2006-05, Vol.50 (6), p.755-760

2006

Volltextzugriff (PDF)

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

Synapse (New York, N.Y.), 2012-06, Vol.66 (6), p.522-532

2012

Volltextzugriff (PDF)

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

Psychopharmacology, 2013-03, Vol.226 (2), p.189-200

2013

Volltextzugriff (PDF)

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

The Journal of pharmacology and experimental therapeutics, 2002-06, Vol.301 (3), p.1020

2002

Volltextzugriff (PDF)

A Novel Augmentation Strategy for Treating Resistant Major Depression

The American journal of psychiatry, 2001-01, Vol.158 (1), p.131-134

2001

Volltextzugriff (PDF)

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

British journal of pharmacology, 2003-02, Vol.138 (4), p.544-553

2003

Volltextzugriff (PDF)

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Journal of medicinal chemistry, 2000-11, Vol.43 (23), p.4333-4353

2000

Volltextzugriff (PDF)

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Neuropsychopharmacology (New York, N.Y.), 1996-02, Vol.14 (2), p.87-96

1996

Volltextzugriff (PDF)

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity

The European journal of neuroscience, 2003-04, Vol.17 (7), p.1403-1410

2003

Volltextzugriff (PDF)

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity

Synapse (New York, N.Y.), 2012-05, Vol.66 (5), p.435-444

2012

Volltextzugriff (PDF)

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Neuropsychopharmacology (New York, N.Y.), 2002-11, Vol.27 (5), p.699-711

2002

Volltextzugriff (PDF)

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat

Neuropharmacology, 2004-02, Vol.46 (2), p.232-242

2004

Volltextzugriff (PDF)

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Neuropsychopharmacology, 2003-09, Vol.28 (9), p.1685-1693

2003

Volltextzugriff (PDF)

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Neuropsychopharmacology (New York, N.Y.), 2001-12, Vol.25 (6), p.871-880

2001

Volltextzugriff (PDF)

Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

European journal of pharmacology, 2001-11, Vol.430 (2-3), p.341-349

2001

Volltextzugriff (PDF)

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Psychopharmacologia, 2002-04, Vol.160 (4), p.353-361

2002

Volltextzugriff (PDF)

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody

The Journal of clinical investigation, 2006-03, Vol.116 (3), p.825-832

2006

Volltextzugriff (PDF)

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats

European journal of pharmacology, 2015-10, Vol.764, p.30-37

2015

Volltextzugriff (PDF)

Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium

European journal of pharmacology, 2000-03, Vol.390 (3), p.245-248

2000

Volltextzugriff (PDF)

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

Neuropsychopharmacology (New York, N.Y.), 2000-09, Vol.23 (3), p.250-262

2000

Volltextzugriff (PDF)

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Neuropsychopharmacology (New York, N.Y.), 2002-12, Vol.27 (6), p.949-959

2002

Volltextzugriff (PDF)

Muscarinic mechanisms of antipsychotic atypicality

Progress in neuro-psychopharmacology & biological psychiatry, 2003-10, Vol.27 (7), p.1125-1143

2003

Volltextzugriff (PDF)

1 – 25 von 86

Suche als RSS-Feed

Aktive Filter

Nur zeigenMit Volltextzugriff

ThemaLife Sciences & Biomedicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(84)

Publikationsform

Artikel
(86)

Sprache

Englisch
(86)
Japanisch
(28)

Erscheinungsjahr

n.n

Thema

Science & Technology
(86)
Animals
(63)
Pharmacology & Pharmacy
(61)
Male
(44)
Biological And Medical Sciences
(41)
Rats
(39)
Medical Sciences
(35)
Pharmacology. Drug Treatments
(32)
Neurosciences & Neurology
(31)
Neuropharmacology
(30)
Humans
(29)
Neurosciences
(29)
Psychology. Psychoanalysis. Psychiatry
(22)
Dose-Response Relationship, Drug
(21)
Psychiatry
(21)
Psychopharmacology
(21)
Mice
(18)
Rats, Sprague-Dawley
(17)
Muscarinic Agonists - Pharmacology
(15)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

The Discovery of Fluoxetine Hydrochloride (Prozac)

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: Implications for treatment of attention-deficit hyperactivity disorder

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

A Novel Augmentation Strategy for Treating Resistant Major Depression

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Brain region and dose effects of an olanzapine/fluoxetine combination on extracellular monoamine concentrations in the rat

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Potent antagonism of 5-HT3 and 5-HT6 receptors by olanzapine

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats

Decreased binding affinity of olanzapine and clozapine for human muscarinic receptors in intact clonal cells in physiological medium

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Muscarinic mechanisms of antipsychotic atypicality

Aktive Filter

Suchergebnisse filtern